Kimberley A. Lentz - Concepedia

Author

Kimberley A. Lentz

Bristol-Myers Squibb (United States)

Also Known As

K. A. Lentz, K.A. Lentz, Kimberley A Lentz, Kimberley A. Lentz, Kimberley Lentz, Kimberly A. Lentz, Lentz, K.A.

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)University of Maryland, Baltimore Pfizer (United States)Research Triangle Park Foundation

About

Kimberley A. Lentz is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	926
2	Natural Sciences	9	9	405
3	Engineering	3	3	215
4	Health Sciences	2	2	120
5	Public Health	1	1	153

Kimberley A. Lentz

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor Kevin W. Gillman, John E. Starrett, Michael F. Parker, ACS Medicinal Chemistry Letters Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryMedicinal ChemistryAlzheimer's Disease	2010	183
Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties Chong‐Hui Gu, Hua Li, Jaquan K. Levons, Pharmaceutical Research NutritionPhysicochemical PropertiesMedicineFood AnalysisChemometric Method	2007	153
Influence of Passive Permeability on Apparent P-glycoprotein Kinetics Kimberley A. Lentz, Joseph W. Polli, Stephen A. Wring, Pharmaceutical Research	2000	126
Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate Sanna Tolle‐Sander, Kimberley A. Lentz, Dean Y. Maeda, Molecular Pharmaceutics	2003	120
Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain Walter A. Kostich, Brian D. Hamman, S. Naidu, Journal of Pharmacology and Experimental Therapeutics	2016	118
Aqueous and cosolvent solubility data for drug-like organic compounds Erik Rytting, Kimberley A. Lentz, Xue-Qing Chen, The AAPS Journal EngineeringMedicineOrganic ChemistryAnalytical ChemistryChemistry	2005	114
Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system Kimberley A. Lentz, Jun Hayashi, Leo J. Lucisano, International Journal of Pharmaceutics EngineeringBiochemistryCaco-2 MonolayersMedicineBioanalysis	2000	91
Development and Validation of a Preclinical Food Effect Model Kimberley A. Lentz, Megan Quitko, Daniel G. Morgan, Journal of Pharmaceutical Sciences Food ChoiceNutritionFood CompositionFood InnovationAgricultural Economics	2006	84
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat Charles F. Albright, Randy Dockens, Jere E. Meredith, Journal of Pharmacology and Experimental Therapeutics	2012	63
A Strategy to Minimize Reactive Metabolite Formation: Discovery of (<i>S</i>)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist Richard A. Hartz, Vijay T. Ahuja, Xiaoliang Zhuo, Journal of Medicinal Chemistry Pharmaceutical ScienceMetabolic CharacterizationReceptor AntagonistPharmacotherapyPharmaceutical Chemistry	2009	54

Page 1